SymbolTRIB
NameTRINITY BIOTECH PLC
SectorHEALTH CARE
RegionEurope
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
AddressIDA BUSINESS PARK,BRAY, CO. WICKLOW, DUBLIN, Ireland
Telephone+353 12769800
Fax
Email
Websitehttps://www.trinitybiotech.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0000888721
Description

Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Ireland of which it derives a majority of its revenues from the Americas segment.

Additional info from NASDAQ:
Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Ireland of which it derives a majority of its revenues from the Americas segment.

2026-08-14 13:32

Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement

Read more
2026-07-22 11:30

Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology

Read more
2026-07-22 11:15

Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change

Read more
2026-07-02 12:30

New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring

Read more
2026-06-30 13:00

Trinity Biotech’s Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Cooling

Read more
2026-06-29 19:15

Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville

Read more
2026-06-23 11:30

Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion Dollar AI Data Center Liquid Cooling Market

Read more
2026-06-23 08:42

New Form 424B3 - TRINITY BIOTECH PLC <b>Filed:</b> 2026-06-23 <b>AccNo:</b> 0001554855-26-001392 <b>Size:</b> 78 KB

Read more
2026-06-16 13:10

Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results

Read more
2026-06-15 13:36

New Form 424B3 - TRINITY BIOTECH PLC <b>Filed:</b> 2026-06-15 <b>AccNo:</b> 0001554855-26-001334 <b>Size:</b> 213 KB

Read more